Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial
A daily probiotic supplement significantly reduces weight regain after diet-induced weight loss, offering a non-drug maintenance approach.
This first RCT of pasteurized A. muciniphila MucT in humans demonstrates that a gut mucosal symbiont supplement, taken daily during weight maintenance, significantly reduces weight regain compared to placebo in adults who lost ≥8% weight on a low-energy diet. The microbiome-based intervention represents a novel, non-pharmaceutical approach to weight maintenance with a safe profile, opening a new class of obesity management strategies.
What the study was
- Study design
- Randomized controlled trial; 8-week LED run-in then 24-week weight maintenance phase
- Population
- Adults with overweight or obesity (n=90) achieving ≥8% weight loss on low-energy diet
- Sample size
- 90
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Nature Medicine
Why it surfaced
First RCT evidence of pasteurized A. muciniphila for weight maintenance in humans. Nat Med publication. Statistically significant primary and secondary endpoints. Novel microbiome-based mechanism distinct from all existing pharmacological approaches. Complements the GLP-1RA landscape by offering a non-drug maintenance option.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.